BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12611068)

  • 1. DLI or second transplant.
    Greinix HT
    Ann Hematol; 2002; 81 Suppl 2():S34-5. PubMed ID: 12611068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.
    Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA
    Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of leukemia relapsed after allogenic bone marrow transplantation with donor lymphocyte infusion: report of 11 cases].
    Sanz Rodríguez C; Steegmann JL; Granda A; de la Cámara R; Figuera A; Arranz R; Gómez-García de Soria V; Alegre A; Fernández-Rañada JM
    Sangre (Barc); 1999 Dec; 44(6):456-63. PubMed ID: 10822760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
    Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L
    Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
    Eapen M; Giralt SA; Horowitz MM; Klein JP; Wagner JE; Zhang MJ; Tallman MS; Marks DI; Camitta BM; Champlin RE; Ringdén O; Bredeson CN; Martino R; Gale RP; Cairo MS; Litzow MR; deLima M
    Bone Marrow Transplant; 2004 Oct; 34(8):721-7. PubMed ID: 15322568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation.
    Yegin ZA; Ozkurt ZN; Aki SZ; Sucak GT
    Transfus Apher Sci; 2010 Jun; 42(3):239-45. PubMed ID: 20385512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
    Savani BN; Montero A; Kurlander R; Childs R; Hensel N; Barrett AJ
    Bone Marrow Transplant; 2005 Dec; 36(11):1009-15. PubMed ID: 16205732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
    Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
    Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
    Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
    Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
    Baker KS; Loberiza FR; Yu H; Cairo MS; Bolwell BJ; Bujan-Boza WA; Camitta BM; Garcia JJ; Ho WG; Liesveld JL; Maharaj D; Marks DI; Schultz KR; Wiernik P; Zander AR; Horowitz MM; Keating A; Weisdorf DJ
    J Clin Oncol; 2005 Oct; 23(28):7032-42. PubMed ID: 16145067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved.
    Massenkeil G; Nagy M; Lawang M; Rosen O; Genvresse I; Geserick G; Dörken B; Arnold R
    Bone Marrow Transplant; 2003 Mar; 31(5):339-45. PubMed ID: 12634724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):116-23. PubMed ID: 17222760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic stem cell transplantation in hematologic malignancy.
    Archuleta TD; Devetten MP; Armitage JO
    Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].
    Slesarchuk OA; Babenko EV; Semenova EV; Bondarenko SN; Éstrina MA; Morozova EV; Paina OV; Vavilov VN; Smirnov BI; Zubarovskaia LS; Afanas'ev BV
    Ter Arkh; 2013; 85(7):26-33. PubMed ID: 24137944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.